The DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.
Matrix Metalloproteinases as New Targets in Alzheimer’s Disease: Opportunities and Challenges
Open accessAbstract
Although matrix metalloproteinases (MMPs) are implicated in the regulation of numerous physiological processes, evidence of their pathological roles have also been obtained in the last decades, making MMPs attractive therapeutic targets for several diseases. Recent discoveries of their involvement in central nervous system (CNS) disorders, and in particular in Alzheimer's disease (AD), have paved the way to consider MMP modulators as promising therapeutic strategies. Over the past few decades, diverse approaches have been undertaken in the design of therapeutic agents targeting MMPs for various purposes, leading, more recently, to encouraging developments. In this article, we will present recent examples of inhibitors ranging from small molecules and peptidomimetics to biologics. We will also discuss the scientific knowledge that has led to the development of emerging tools and techniques to overcome the challenges of selective MMP inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MMPs are known to be linked to extracellular protein degradation including Aβ (72), whereas MMPs upregulated in AD may also confer neuroinflammation, synaptic dysfunction, and neuronal death (73, 74).”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [74]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
On the size of the active site in proteases. I. Papain
Schechter, I., & Berger, A. (1967) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(67)80055-x · Cited by 5,256
How Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959
Structure and function of matrix metalloproteinases and TIMPs
Nagase, H., Visse, R., & MURPHY, G. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.12.002 · Cited by 3,507
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Matrix metalloproteinases and the regulation of tissue remodelling
Page-McCaw, A., Ewald, A. J., & Werb, Z. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2125 · Cited by 2,630
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
Tissue inhibitors of metalloproteinases: evolution, structure and function
Brew, K., Dinakarpandian, D., & Nagase, H. (2000) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(99)00279-4 · Cited by 1,932
Matrix metalloproteinases as modulators of inflammation and innate immunity
Parks, W. C., Wilson, C. L., & López-Boado, Y. S. (2004) · Nature Reviews Immunology · doi:10.1038/nri1418 · Cited by 1,929
Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction
Nation, D. A., Sweeney, M. D., Montagne, A., Sagare, A. P., D’Orazio, L. M., Pachicano, M., Sepehrband, F., Nelson, A. R., Buennagel, D. P., Harrington, M. G., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0297-y · Cited by 1,728
Research works printed but not linked: 4
- Asahina M., 2001, Clin. Neuropathol., 20, 60
- 10.1523/JNEUROSCI.1880-05.2006 · DOI
- Hayashita-Kinoh H., 2001, Cell Growth Differ., 12, 573
- Llano E., 1999, Cancer Res., 59, 2570
Cited by
Sorted by citations
Behl, T., Kaur, G., Sehgal, A., Bhardwaj, S., Singh, S., Buhaș, C. L., Pusta, C. T. J., Uivaroșan, D., Munteanu, M. A., & BUNGAU, S. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031413 · Cited by 198
The immunomodulatory role of matrix metalloproteinases in colitis-associated cancer
He, L., Kang, Q., Chan, K. I., Zhang, Y., Zhong, Z., & Tan, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1093990 · Cited by 151
Microglial activation states and their implications for Alzheimer's Disease
Valiukas, Z., Tangalakis, K., Apostolopoulos, V., & Feehan, J. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100013 · Cited by 167
Protein Misfolding and Aggregation in Proteinopathies: Causes, Mechanism and Cellular Response
Ajmal, M. R. (2023) · Diseases · doi:10.3390/diseases11010030 · Cited by 116
Wareham, L. K., Baratta, R. O., Buono, B. J. D., Schlumpf, E., & Calkins, D. J. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00704-0 · Cited by 111
Metadata
- Authors
- Zipfel, P., Rochais, C., Baranger, K., Rivera, S., & Dallemagne, P.
- Affiliations
- Centre d'Etudes et de Recherche sur le Médicament de Normandie (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Dallemagne, Patrick
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-05-27
- Volume
- 63
- Issue
- 19
- Pages
- 10705-10725
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3029030457
- Cited by
- 94
- References
- 224
- Citations by year
- 2026: 11 · 2025: 23 · 2024: 20 · 2023: 15 · 2022: 13 · 2021: 10 · 2020: 2
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- green
- arxiv.org
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- arXiv (Cornell University) (submittedVersion)
- HAL (submittedVersion, other-oa)
- arXiv (Cornell University)
- Funders
- Agence Nationale de la Recherche
- European Regional Development Fund
- Aix-Marseille Universit?
- Centre National de la Recherche Scientifique
- Association France Alzheimer
- R?gion Normandie
- Excellence Initiative of Aix-Marseille Universit?
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- matrix metalloproteinases, Alzheimer's disease, matrix metalloproteinase inhibitors, therapeutic target, peptidomimetics, small molecule inhibitors, central nervous system disorders
- MeSH terms
- Alzheimer Disease, Central Nervous System, Humans, Drug Delivery Systems, Matrix Metalloproteinases, Peptidomimetics, Matrix Metalloproteinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
